Monte Rosa Therapeutics (GLUE) Depreciation and Depletion (2020 - 2026)

Monte Rosa Therapeutics' Depreciation and Depletion history runs 7 years deep, the most recent figure standing at $2.0 million for Q1 2026.

• In Q1 2026, Depreciation and Depletion rose 1.45% year-over-year to $2.0 million; the TTM figure through Mar 2026 stood at $8.3 million (up 1.37% YoY), while the FY2025 annual figure was $8.4 million, up 2.89% from the prior year.
• Depreciation and Depletion was $2.0 million for Q1 2026 at Monte Rosa Therapeutics, down from $2.1 million in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $2.1 million in Q2 2025 to a low of $800000.0 in Q1 2022.
• Historically, Depreciation and Depletion has averaged $1.7 million across 5 years, with a median of $1.9 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Depreciation and Depletion soared 191.97% in 2022, then decreased 0.38% in 2025.
• A 5-year view of Depreciation and Depletion shows it stood at $1.0 million in 2022, then soared by 77.95% to $1.8 million in 2023, then grew by 12.99% to $2.1 million in 2024, then advanced by 1.31% to $2.1 million in 2025, then fell by 2.83% to $2.0 million in 2026.
• The last three Depreciation and Depletion figures came in at $2.0 million (Q1 2026), $2.1 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.